Below are the financial statements of Genscript Biotech, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of USD | 2024 | 2023 |
|---|---|---|
| Continuing operations revenue | 594.49a | 560.48a |
| Cost of sales | -322.36a | -289.85a |
| Gross profit | 272.13a | 270.63a |
| Other income and gains | 39.22a | 37.88a |
| Selling and distribution expenses | -88.12a | -80.14a |
| Administrative expenses | -114.38a | -106.82a |
| Research and development expenses | -53.79a | -52.7a |
| Fair value (losses)/gains of preferred shares and warrants | -123.58a | 129.21a |
| Other expenses | -3.1a | -5.61a |
| Share of losses of associates | — | — |
| Investment in a significant associate | -37.75a | 0a |
| Investments in other associates | -1.32a | -1.38a |
| Finance costs | -8.03a | -5.74a |
| Provision for impairment of long-lived assets | -45.51a | -11.66a |
| Provision for impairment of financial assets, net | -6.56a | -4.78a |
| Loss/profit before tax from continuing operations | -170.8a | 168.89a |
| Income tax expense | -2.98a | -6.01a |
| Loss/profit for the year from continuing operations | -173.77a | 162.88a |
| Discontinued operation | — | — |
| Loss for the period from Legend, net of tax | -203.15a | -518a |
| Gain on deconsolidation of Legend, net of tax | 3,232.21a | 0a |
| Profit/(loss) for the year from discontinued operation | 3,029.06a | -518a |
| Profit/(loss) for the year | 2,855.29a | -355.12a |
| Attributable to | — | — |
| Owners of the parent | 2,961.88a | -95.48a |
| Non-controlling interests | -106.59a | -259.64a |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Genscript Biotech’s data sources below and access millions more through our Disclosure Search.